Ulipristal Acetate — Active Pharmaceutical Ingredient

Ulipristal Acetate is an active pharmaceutical ingredient found in 2 FDA-approved drug products. Forms: TABLET. Routes: ORAL.

This content is for informational purposes only. Always consult a healthcare professional.

Ulipristal Acetate (2 brand names, 1 dosage form, 1 route)

Available dosage forms: TABLET.

Routes of administration: ORAL.

Brand Names

  • ELLA
  • LOGILIA

Indications and Usage

Ellais a progesterone agonist/antagonist emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure [see Dosage and Administration (2.1)] . Ellais not intended for routine use as a contraceptive.

Contraindications

Ellais contraindicated for use in the case of known or suspected pregnancy [see Use in Specific Populations (8.1)].

Drug Interactions

Several in vivodrug interaction studies have shown that ellais predominantly metabolized by CYP3A4.

Mechanism of Action

When taken immediately before ovulation is to occur, ella postpones follicular rupture. The likely primary mechanism of action of ulipristal acetate for emergency contraception is therefore inhibition or delay of ovulation; however, alterations to the endometrium that may affect implantation may also contribute to efficacy.

Overdosage

Experience with ulipristal acetate overdose is limited. In a clinical study, single doses equivalent to up to 4 times ellawere administered to a limited number of subjects without any adverse reactions.

⚠ Caution
Medical Disclaimer: This information is for educational purposes only. Always consult a healthcare professional before taking any medication.